Portal de investigación
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Calleja, JL
- Crespo, J
- Rincon, D
- Ruiz-Antoran, B
- Fernandez, I
- Perello, C
- Gea, F
- Lens, S
- Garcia-Samaniego, J
- Sacristan, B
- Llerena, S
- Pascasio, JM
- Turnes, J
- Torras, X
- Morillas, RM
- Llaneras, J
- Serra, MA
- Diago, M
- Rodriguez, CF
- Ampuero, J
- Jorquera, F
- Simon, MA
- Arenas, J
- Navascues, CA
- Bañares R
- Muñoz R
- Albillos, A
- Mariño Z
- Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collab
Grupos
Abstract
Background & Aims: Clinical trials evaluating second-generation direct-acting antiviral agents (DAAs) have shown excellent rates of sustained virologic response (SVR) and good safety profiles in patients with chronic hepatitis C virus (HCV) genotype 1 infection. We aimed to investigate the effectiveness and safety of two oral DAA combination regimens, ombitasvir/paritaprevir/rito navir plus dasabuvir (OMV/PTV/r + DSV) and ledipasvir/sofosbuvir (LDV/SOF), in a real-world clinical practice. Methods: Data from HCV genotype 1 patients treated with either OMV/PTV/r + DSV +/- ribavirin (RBV) (n = 1567) or LDV/SOF +/- RBV (n = 1758) in 35 centers across Spain between April 1, 2015 and February 28, 2016 were recorded in a large national database. Demographic, clinical and virological data were analyzed. Details of serious adverse events (SAEs) were recorded. Results: The two cohorts were not matched with respect to baseline characteristics and could not be compared directly. The SVR12 rate was 96.8% with OMV/PTVr/DSV +/- RBV and 95.8% with LDV/SOF +/- RBV. No significant differences were observed in SVR according to HCV subgenotype (p = 0.321 [OMV/PTV/r + DSV +/- RBV] and p = 0.174 [LDV/SOF]) or degree of fibrosis (c0.548 [OMV/PTV/r/DSV +/- RBV] and p = 0.085 [LDV/SOF]). Only baseline albumin level was significantly associated with failure to achieve SVR (p < 0.05) on multivariate analysis. Rates of SAEs and SAE-associated treatment discontinuation were 5.4% and 1.7%, in the OMV/PTV/r + DSV subcohort and 5.5% and 1.5% in the LDV/SOF subcohort, respectively. Hepatocellular carcinoma (HCC) recurred in 30% of patients with a complete response to therapy for previous HCC. Incident HCC was reported in 0.93%. Conclusions: In this large cohort of patients managed in the real-world setting in Spain, OMV/PTV/r + DSV and LDV/SOF achieved high rates of SVR12, comparable to those observed in randomized controlled trials, with similarly good safety profiles. Lay summary: In clinical trials, second-generation direct-acting antiviral agents (DAAs) have been shown to cure over 90% of patients chronically infected with the genotype 1 hepatitis C virus and have been better tolerated than previous treatment regimens. However, patients enrolled in clinical trials do not reflect the real patient population encountered in routine practice. The current study, which includes almost 4,000 patients, demonstrates comparable rates of cure with two increasingly used DAA combinations as those observed in the clinical trial environment, confirming that clinical trial findings with DAAs translate into the real-world setting, where patient populations are more diverse and complex. (c) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0168-8278, 1600-0641
- Tipo:
- Article
- Páginas:
- 1138-1148
- PubMed:
- 28189751
- Factor de Impacto:
- 5,633 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF HEPATOLOGY ELSEVIER
Citas Recibidas en Web of Science: 155
Documentos
- No hay documentos
Filiaciones
Keywords
- Hepatitis C; Chronic; Genotype 1; Ombitasvir; Paritaprevir; Ritonavir; Dasabuvir; Ledipasvir; Sofosbuvir; Real-world; Antiviral agents; Sustained virologic response; Randomized controlled trials